These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30134599)

  • 1. Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa.
    Demine S; Balhuizen A; Debaille V; Joosten L; Fereau M; Chilla SNM; Millard I; Scharfmann R; Egrise D; Goldman S; Marchetti P; Gotthardt M; Laurent S; Burtea C; Eizirik DL
    Molecules; 2018 Aug; 23(9):. PubMed ID: 30134599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells.
    Burtea C; Laurent S; Crombez D; Delcambre S; Sermeus C; Millard I; Rorive S; Flamez D; Beckers MC; Salmon I; Vander Elst L; Eizirik DL; Muller RN
    Contrast Media Mol Imaging; 2015; 10(5):398-412. PubMed ID: 25930968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and characterization of a cell-permeable bimodal contrast agent targeting β-galactosidase.
    Keliris A; Ziegler T; Mishra R; Pohmann R; Sauer MG; Ugurbil K; Engelmann J
    Bioorg Med Chem; 2011 Apr; 19(8):2529-40. PubMed ID: 21459584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice.
    Demine S; Garcia Ribeiro R; Thevenet J; Marselli L; Marchetti P; Pattou F; Kerr-Conte J; Devoogdt N; Eizirik DL
    Diabetologia; 2020 Apr; 63(4):825-836. PubMed ID: 31873789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection.
    Ta R; Suchy M; Tam JH; Li AX; Martinez-Santiesteban FS; Scholl TJ; Hudson RH; Bartha R; Pasternak SH
    Contrast Media Mol Imaging; 2013; 8(2):127-39. PubMed ID: 23281285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
    Tan M; Burden-Gulley SM; Li W; Wu X; Lindner D; Brady-Kalnay SM; Gulani V; Lu ZR
    Pharm Res; 2012 Apr; 29(4):953-60. PubMed ID: 22139536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.
    Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR
    Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
    Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
    Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination.
    Ruprecht N; Parakkattel D; Hofmann L; Broekmann P; Lüdi N; Kempf C; Heverhagen JT; von Tengg-Kobligk H
    Invest Radiol; 2024 May; 59(5):372-378. PubMed ID: 37824716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
    Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
    Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging.
    Kalber TL; Kamaly N; So PW; Pugh JA; Bunch J; McLeod CW; Jorgensen MR; Miller AD; Bell JD
    Mol Imaging Biol; 2011 Aug; 13(4):653-62. PubMed ID: 20809208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.
    Wu X; Burden-Gulley SM; Yu GP; Tan M; Lindner D; Brady-Kalnay SM; Lu ZR
    Bioconjug Chem; 2012 Aug; 23(8):1548-56. PubMed ID: 22812444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
    Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1841-1855. PubMed ID: 38372766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F; Wang X; Lei H
    Carbohydr Res; 2014 Aug; 395():9-14. PubMed ID: 24995911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.
    Chen SH; Kuo YT; Singh G; Cheng TL; Su YZ; Wang TP; Chiu YY; Lai JJ; Chang CC; Jaw TS; Tzou SC; Liu GC; Wang YM
    Inorg Chem; 2012 Nov; 51(22):12426-35. PubMed ID: 23116118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide.
    Park JA; Lee YJ; Ko IO; Kim TJ; Chang Y; Lim SM; Kim KM; Kim JY
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):246-50. PubMed ID: 25449282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interplay of T1- and T2-relaxation on T1-weighted MRI of hMSCs induced by Gd-DOTA-peptides.
    Cao L; Li B; Yi P; Zhang H; Dai J; Tan B; Deng Z
    Biomaterials; 2014 Apr; 35(13):4168-74. PubMed ID: 24560458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer.
    Tan M; Ye Z; Lindner D; Brady-Kalnay SM; Lu ZR
    Pharm Res; 2014 Jun; 31(6):1469-76. PubMed ID: 23471641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasmall graphene oxide based T
    Zhang M; Liu X; Huang J; Wang L; Shen H; Luo Y; Li Z; Zhang H; Deng Z; Zhang Z
    Nanomedicine; 2018 Oct; 14(7):2475-2483. PubMed ID: 28552648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent.
    Park JA; Lee JJ; Jung JC; Yu DY; Oh C; Ha S; Kim TJ; Chang Y
    Chembiochem; 2008 Nov; 9(17):2811-3. PubMed ID: 18956393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.